How many drugs treat Acute coronary syndrome?

Drug Landscape tracks 8 marketed treatments for Acute coronary syndrome (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-coronary-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute coronary syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute coronary syndrome (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute coronary syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Effient	PRASUGREL	Cosette	P2Y12 Platelet Inhibitor	P2Y purinoceptor 12	2009-01-01
Integrilin	EPTIFIBATIDE	Merck & Co.	Platelet Aggregation Inhibitor [EPC]	Integrin alpha-IIb/beta-3	1998-01-01
Aggrastat	TIROFIBAN	Medicure	Platelet Aggregation Inhibitor	Integrin alpha-IIb/beta-3	1998-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Lopressor	metoprolol	Generic (originally Ciba-Geigy/Novartis)	Beta-1 selective blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A	1978-08-07
Brilinta	Brilinta	AstraZeneca		Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Brilinta	ticagrelor	AstraZeneca	P2Y12 Platelet Inhibitor [EPC]	Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
integrilin	integrilin	University of Cincinnati		Integrin alpha-IIb/beta-3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 2 drugs in Acute coronary syndrome
Cosette · 1 drug in Acute coronary syndrome
Generic (originally Ciba-Geigy/Novartis) · 1 drug in Acute coronary syndrome
Generic (originally Sanofi/BMS) · 1 drug in Acute coronary syndrome
Medicure · 1 drug in Acute coronary syndrome
Merck & Co. · 1 drug in Acute coronary syndrome
· 1 drug in Acute coronary syndrome
University of Cincinnati · 1 drug in Acute coronary syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute coronary syndrome:

Cite this brief

Drug Landscape (2026). Acute coronary syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-coronary-syndrome. Accessed 2026-06-10.

Acute coronary syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing